call. and Thank release reschedule you, begin earnings you I'll providing for appreciate today's the our afternoon, Paul, to good conference and some We joining call. everyone. context by decision
selected that in note our well flow as You will we information. year-to-date press and limited cash reported third sheet balance quarter and results as release,
As in as December tax an review process, tax understatement benefit part XXXX, of resulting on company's the statement. quarterly its company deferred determined of the our state was liability reflected XX, the overstated income of that income
the flow, any While company's items it to on we management or while noncash prior Form impact ended compliance, the that third correct full statements. period information covenant on XX-Q and cash have work have XX, of report to our do concluded year-to-date appropriate quarterly of historical quarter compensation delay our filing financial we XXXX, these for the is and period the September disclosure earnings not liquidity,
work we financial much regarding this as and complete position. in near the sharing and as results are to at current our time accordingly, expect this information can We future
my our call. from move I'll X the with Slide you away that, With open key and remarks messages to take I'd to like
continued QX, strengthening During to we the the business. make fundamentals of progress
There on were the As be several we announced key customers. in forward in to and August, our maintaining key the commitments medical highlights focus businesses CDMO our while quarter. NARCAN going will countermeasure
led by individuals. access As channels. Paul, to in treatment September, to public shelves NARCAN and you've we business interest opportunity about The heard and OTC to NARCAN from excited hit overdose the all critical sales opioid this strong and overall had retail expand are Canadian just the Haywood
expectations in for countermeasures, QX. our medical line In was procurement with
also first primarily FDA-approved shipment franchise completed CYFENDUS was VIGIV. the had smallpox The of positive the September, sales, driven in by and
Our focus third decision CDMO cost in existing to deemphasize customers, the supported our quarter. on efforts reduction and
previously guidance solid of organization quarter, expectations. exceed slightly run in our in exceeded in our will revenue $XXX the across million range. the of costs also actions exceeding EBITDA As beginning of disclosed, had quarter was expect we full these first strong the we which rate Adjusted annualized the reduced quarter, XXXX. the Overall,
development to facility testament customers XXXX. and return after the moment of by like to efforts and extensive facility to is to of our our take warning since Camden going August was operations remediation the support a out as This the and positive normal skill teams highlight quality our dedication existing closed a completed I'd that to position forward. FDA letter operations we the acknowledgment
now interest We've continued our NARCAN this preparedness the our updated reflect for over-the-counter key year. the momentum of our overdoses. and retail public opioid for customers driver XXXX rest threat as A Canadian sales guidance in increased the to of seek expectations is
CYFENDUS uncertainty medical On the largely for government of our timing regarding the funding remains forecast with remaining the XXXX some side, countermeasures procurement. intact U.S. sales
we result, guidance our are ranges. a widening As
to With the those turn now numbers. key updates, let's
$XXX and including As NARCAN market durability CYFENDUS indicated to the momentum from the Stockpile. quarterly driven the continued $XX public U.S. XX U.S. include of sales of and revenues in and deeper OTC third the the adjusted public Canada. Biofracs million. NARCAN driven this primarily interest demonstrating million, market market, into in retail on Canada growing and launch from and in EBITDA by of of total Diving million, Slides include revenues, strength $XXX of million, channel Strategic the $XX government's XX, highlights consistent items of sales product quarter NARCAN the demand of the important the deliveries MCM interest National U.S. by and Anthrax
million channels. contributions million, $XX reflects were our CDMO were including sales Revenue in $XX retail service on the also combined existing from lease quarter to NARCAN BAT of product transition $XX solid includes the OTC customers. And sales focus continued other launch revenues NCM Smallpox initial into and million, of sales.
to CDMO expenses, BAT. the quality Camden sales investments to $XX by sales CDMO expenses. anthrax and of Cost offset production million, Cost driven site. network August initiatives reduce on in the reduced product taken $XXX of operating million the of across reflects Turning at of in quarter by improvement actions and X was the NARCAN,
was key $XX expense NARCAN expense million, initiatives. was supporting SG&A and expenses million R&D including $XX
also We our a capitalization. quarter was interest medical the countermeasures. and a higher lower in $XXX rates incurred related charge primarily million The impairment impairment result of noncash to market goodwill
this million, the move anthrax XX NARCAN, segment quarter. XX%. Overall, was and revenues long-term $XXX or adjusted in With million we review driven gross of continue BAT that, area let's $XXX the Products to were and and business. In segment, margin the during value by performance Slide to see
Services As gross adjusted and revenues million. negative margin for million segment, $XX $XX were the was
of versus balance our quarter Moving the availability with in select facility. flat on XXXX third requirements revolving credit by with senior $XX of our XX, liquidity touch the collection and connection and This to credit amendment reflects $XX Slide debt of XXXX. ended and sheet flow on facility. receivable, We roughly was repayments of to secured made the accounts million $XXX cash offset liquidity, the increased May including second cash million million the Total highlights. in quarter total cash under I'll
positive in period in And and million. the was flow [ net of September $XX position were expenditures XXXX, debt our ] cash was as XX, the Operating capital quarter million. $XXX
of position derisk our some to we've significant on we've XXXX, capital financial structure business. this the year. our recap steps now taken I'll made and strengthen progress the Throughout
shift source divestiture, actions a have over million business operating executed Health a of implemented the strategic $XXX and Travel annualized our to growth. We CDMO of expense deemphasize save announced to as
receipt and our for FDA ACAM, also of milestones credit about including in We and operations CYFENDUS growth OTC, Big and and same the our ongoing core healthy. amended for the XXXX. extended positive long-term achieved NARCAN. At our of of and orders May facility of and short, new time, the sound U.S. we've are secured business, maturity $XXX products core of In the business government Ebonga the to RSDL contracts NARCAN fundamentally BAT, approvals million
near to capital make our business profile, our We'll you optimizing informed our term, on are our result. focus further to access will confident the keep maintain as improve and Over strengthen this medium we platform will that a we we and as to journey. progress on credit
to please XX. see Turning Slide guidance,
our XXXX As evening, offset of the to announced with follows: prior guidance to potential in forecasting timing our just discussed a Total we remaining than product. XXXX CYFENDUS million our related procurement. full strength the press guidance CYFENDUS related XXXX revenues by guidance consistent as to to given as $X we of $XXX release Anthrax of timing funding year the NCM million, remaining this is updating FDA-approved sales range NARCAN the $X.X are $XXX prior ongoing billion for wider the uncertainty of procurement billion, We're
While funding status unable are we the public XXXX. Nasal $XX of before in forecasting of to to launch end the and in confidence of have interest the NARCAN robust $XXX our million to by increase primarily this million, the U.S. to channel, midpoint $XXX prior at Spray the over given the aligned quarter sales an guidance continuing of demand OTC deliveries reflecting million conversations U.S. Canada September timing from with of We're government's year-end, the NARCAN the resolution. are absolute date
We expect remainder XXXX. $XXX the the million guidance. sales of at for smallpox the million, reduction $X midpoint timing shift reflects reduction prior $XXX of to international million a sales of from MCM The a of
primarily other of We're revenue at sales which in RSDL. million $XXX the range. million, guidance, $XXX slight reduction expect is revenue reflecting our million within for from We million forecasting prior midpoint a of million, to $XX reduction of $X $XX expectations product previous to CDMO a
of Shifting metrics. positive to of potential between costs. margin prior the decrease guidance $XX as points from to onetime million And reduction the range. $XX remaining gross guidance as We're range reflects at $XX funding range. XXXX procurement CYFENDUS and, adjusted we're well to XX% This forecasting the million timing EBITDA profitability for a XXX the at basis a of potential the finally, from negative of forecasting midpoint prior XX% midpoint adjusted the million,
turn please comments. Slide XX to summary conclude, for some To
our in the on and results strong, on focusing and third of to important profitability driving improving progress quarter CDMO balance to we products, delivered sheet. on Our variety our were our by existing fundamentals a strengthen milestones. our We're customers, core serving continuing business initiative
Camden milestone across key We continue compliance quality closeout and organization strengthen facility. with our the warning the to achieved a at our and letter
remarks. for provides remarks, upon to a short, call for In prepared QX through to progress strength build my our business closing over now completes Haywood foundation the turn forward. and and the That I'll going
